RxDoctor Payments Data

Aliza Kumpinsky, MD

Neurological Surgery · Philadelphia, PANPI 1235542465

Payments from drug & device makers

$394in general payments, 2019–2025

Across 18 payments — averaging $21.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$175
  • Novartis$51
  • Amgen$42
  • Amneal Pharmaceuticals LLC$28
  • Lilly USA, LLC$28
  • Dr.reddy's Laboratories,inc.$27
  • plus $44 from 3 others

What the payments were for

  • Food & beverage$394100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$394 in reported general payments places this provider in the 20th percentile of 390 neurological surgery providers in Pennsylvania.

See all neurological surgery providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$11,946
Medicare patients
18
Services billed
1,245

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Ajovy AutoinjectorFremanezumab-Vfrm81$47,115
UbrelvyUbrogepant52$43,365
Emgality PenGalcanezumab-Gnlm49$36,967
ReyvowLasmiditan Succinate18$13,686
QuliptaAtogepant13$12,827
Sumatriptan24$2,780
Carbamazepine12$2,027
Gabapentin51$1,862
Sumatriptan Succinate52$1,730
Topiramate47$1,250
Divalproex Sodium14$1,098
Levetiracetam28$1,035
RizatriptanRizatriptan Benzoate60$746
Butalbital-Acetaminophen-CaffeButalb/Acetaminophen/Caffeine51$746
Pregabalin27$731

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCReyvow, Olanzapine$28$13,80131 claims
Dr.reddy's Laboratories,inc.Divalproex Sodium, Levetiracetam, Pregabalin, Lamotrigine$27$3,18785 claims
Upsher-smith Laboratories LLCTopiramate$16$1,25047 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 390 neurological surgery providers in Pennsylvania.

Other neurological surgery in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →